GlassScriptPhysician profile
Long Her
NPI 1124697255
$703.46
in general payments reported to CMS, 2019-2025
14 companies · $518 in 2025
The $518 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $185 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $703.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $703.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $92.40 | 2024-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $91.25 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $85.62 | 2024-2025 | |
| Pfizer INC. | $84.67 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.49 | 2024-2025 | Jardiance |
| Exact Sciences Corporation | $72.86 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Dexcom, INC. | $59.73 | 2024-2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.84 | 2025 | Caplyta |
| Collegium Pharmaceutical, INC. | $20.88 | 2025 | Jornay Pm |
| Lilly USA, LLC | $19.68 | 2025 | Zepbound, Mounjaro |
| Ibsa Pharma INC. | $17.50 | 2024 | Tirosint, Licart |
| Glaxosmithkline, LLC. | $15.24 | 2025 | Shingrix, Bexsero, Pediarix |
| Philips North America LLC | $14.68 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Phathom Pharmaceuticals, INC. | $11.62 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Long Her listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.